India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

The High Court of Delhi has issued a temporary injunction blocking four Indian drug-makers from launching generic versions of Bristol-Myers’ top-selling anticoagulant apixaban.

Indian companies should post “healthy” growth in 2020, helped by a robust domestic market and abating US pricing pressures, analysts say.

Arun Kumar is stepping down as chief executive of Strides Pharma to focus on overall corporate strategy and the company’s return to injectables. He will be replaced by former Cipla chief operating officer R Ananthanarayanan.

India’s Sun Pharma has sought leave to appeal a US court ruling rejecting the company’s bid for dismissal of a multidistrict antitrust lawsuit involving its troubled Ranbaxy subsidiary.

Piramal Enterprises, one of India’s biggest conglomerates, has said it is looking to sell up to a 20% stake in its Piramal Healthcare business to raise funds for spurring growth of the division through acquisitions.